CCL Pharmaceuticals (Pvt.) Limited
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-headquartered pharmaceutical and healthcare company with manufacturing operations and a multi-country commercial presence.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- 65, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore, Pakistan
- Website
- cclpharma.com ↗
- Phone
- +92 42 111 225 678
- Official contact
- Contact page ↗
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| MOLOX | Moxifloxacin | 400 mg | Tablet | 5's | 042716 | PKR 994.57 | PKR 198.91/tablet | 8% above median |
| MYCOLE | Fluconazole | 50 mg | Capsule | 7's | 031679 | PKR 849.76 | PKR 121.39/capsule | Near median |
| MYCOLE | Fluconazole | 150 mg | Capsule | 1's | 031680 | PKR 303.48 | PKR 303.48/capsule | 15% above median |
| MYCOLE | Fluconazole | 200 mg | Capsule | 4's | 031681 | PKR 1,618.57 | PKR 404.64/capsule | 83% above median |
| NEO-KLAR | Clarithromycin | 125 mg/5 mL | Dry suspension | 30 ml | 024995 | PKR 247.84 | PKR 8.26/mL | 14% above median |
| NEO-KLAR | Clarithromycin | 250 mg/5 mL | Dry suspension | 70ml | 088485 | PKR 885.73 | PKR 12.65/mL | 12% above median |
| NEO-KLAR SR | Clarithromycin | 500 mg | Tablet | 5's | 062781 | PKR 441.47 | PKR 88.29/tablet | 6% above median |
| NEO-KLAR SR | Clarithromycin | 500 mg | Sustained-release tablet | 1's | 062781 | PKR 95.97 | PKR 95.97/tablet | No comparator |
| PANACEF | Ceftazidime | 250 mg | Injection | Vial | 023858 | PKR 167.85 | PKR 167.85/vial/unit | Near median |
| PANACEF | Ceftazidime | 1 g | Injection | Vial | 023986 | PKR 479.57 | PKR 479.57/vial/unit | Near median |
| PIPBACTA | Piperacillin + tazobactam | 2 g + 0.25 g | Injection | 1's | 112903 | PKR 720.05 | PKR 720.05/vial/unit | Near median |
| RADIAL | Linezolid | 600 mg | Tablet | 12's | 065789 | PKR 5,200.51 | PKR 433.38/tablet | 10% above median |
| RADIAL | Linezolid | 2 mg | IV infusion | 100ml | 069427 | PKR 726.96 | PKR 7.27/mL | 63% above median |
| RADIAL | Linezolid | 400 mg | Tablet | 12's | 079717 | PKR 3,057.00 | PKR 254.75/tablet | 11% above median |
| RADIAL | Linezolid | 600 mg/300 mL | IV infusion | 1's | 099559 | PKR 963.44 | PKR 963.44/vial/unit | 21% below median |
| Riconza | Itraconazole | 100 mg | Capsule | 4's | 096602 | PKR 594.63 | PKR 148.66/capsule | Near median |
| RITLO | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 102299 | PKR 12,331.98 | PKR 102.77/tablet | 7% above median |
| RITLO | Lopinavir + Ritonavir | 100 mg + 25 mg | Tablet | 120's | 111913 | PKR 8,957.74 | PKR 74.65/tablet | Near median |
| SANRUI | Oseltamivir | 75 mg | Capsule | 10's | 102300 | PKR 1,204.29 | PKR 120.43/capsule | Near median |
| SNARE | Ceftriaxone | 500 mg | Powder for IV injection | 1 Vial | 093509 | PKR 330.06 | PKR 330.06/vial/unit | 5% above median |
| SNARE | Ceftriaxone | 250 mg | IV injection | 1's | 109388 | PKR 208.59 | PKR 208.59/vial/unit | 12% above median |
| SNARE | Ceftriaxone | 1 g | IM injection | 1's | 109389 | PKR 662.95 | PKR 662.95/vial/unit | 6% above median |
| TACAVIR | Entecavir | 0.5 mg | Tablet | 30's | 055321 | PKR 21,357.15 | PKR 711.91/tablet | 100% above median |
| TACAVIR | Entecavir | 1 mg | Tablet | 30's | 055322 | PKR 35,595.25 | PKR 1,186.51/tablet | 105% above median |
| TACAVIR | Entecavir | 0.05 mg/mL | Oral suspension | 210ml | 062779 | PKR 9,526.97 | PKR 45.37/mL | No comparator |
| TENOVIR | Tenofovir disoproxil | 300 mg | Tablet | 30's | 065743 | PKR 7,125.30 | PKR 237.51/tablet | 6% above median |
| VONAL | Voriconazole | 200 mg | Tablet | 10's | 097644 | PKR 1,766.30 | PKR 176.63/tablet | 15% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.